Gastric Cancer Drugs Market Performance and Future Outlook at 10.7% CAGR Through 2029

Uncover key drivers, emerging technologies, and competitive movements shaping the gastric cancer drugs market from 2025–2034 with trusted insights from The Business Research Company

What Is The Predicted Size Of The Gastric Cancer Drugs Industry By 2029?

The market for gastric cancer drugs has experienced substantial growth in recent years. It is anticipated to expand from $4.41 billion in 2024 to $4.9 billion in 2025, at a compound annual growth rate (CAGR) of 11.2%. The expansion observed in the past can be attributed to factors like a rise in pharmaceutical R&D expenditure, increased healthcare spending, robust economic growth in emerging markets, and a rapid increase in the elderly population.

The market for gastric cancer medications is projected to expand quickly over the coming years, anticipated to reach “$7.35 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.7%. This expansion during the forecast period is driven by factors such as a higher incidence rate of gastric cancer, a robust drug pipeline, an increase in acquisitions and partnerships, rising healthcare spending, a growing elderly population, and updated FDA regulations designed to accelerate biologics drug development. Key trends anticipated during this period involve strategic collaborations and agreements aimed at diversifying product portfolios, forging partnerships with other firms or governmental organizations, intensifying pipeline studies for gastric cancer drug development, investing in AI solutions to lower R&D expenses, advancing next-generation biologics, and incorporating CRISPR-cas9 technology into novel drug development efforts.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp

What Major Drivers Are Impacting The Gastric Cancer Drugs Market?

The growing number of obesity cases and the expanding smoking population have led to an elevated count of individuals suffering from gastric cancer. Consuming tobacco and adhering to an unhealthy diet elevates the risk of stomach cancer. For example, in May 2023, the Government Digital Service, a UK-based government entity, reported that in England, approximately 25.9% of persons (18 years and older) were obese in 2022–2022, marking an increase of 25.2%. This rise in gastric cancer cases is anticipated to propel the expansion of the gastric cancer drugs market.

Which Segment Categories Are Driving Maximum Growth In The Gastric Cancer Drugs Market?

The gastric cancer drugs market covered in this report is segmented –

1) By Type: Imatinib, Trastuzumab, Other Types

2) By Route of Administration: Oral, Parenteral

3) By End User: Hospitals, Clinics, Cancer Speciality Centers

Subsegments:

1) By Imatinib: Oral Formulations, Injectable Formulations, Combination Therapies

2) By Trastuzumab: Monotherapy, Combination Therapy With Chemotherapy, Biosimilars Of Trastuzumab

3) By Other Types: Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications

Which Long-Term Trends Will Play A Crucial Role In The Gastric Cancer Drugs Market?

Companies operating in the gastric cancer drugs market are actively developing advanced products, such as anti-PD-1 therapies, to improve treatment efficacy and patient outcomes. Anti-PD-1 therapy is a form of immunotherapy that targets the programmed cell death protein 1 (PD-1) receptor on immune cells. For example, in November 2023, Merck & Co., Inc., a US-based pharmaceutical company, obtained approval from the Food and Drug Administration (FDA), a US-based federal agency dedicated to protecting public health, for KEYTRUDA (pembrolizumab). KEYTRUDA (pembrolizumab) is an anti-PD-1 therapy utilized for treating gastric cancer. It is indicated for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. This specific indication is for use in combination with trastuzumab, as well as fluoropyrimidine- and platinum-containing chemotherapy. The accelerated approval for this indication was based on the tumor response rate and the duration of the response.

Who Are The Dominant Players In The Gastric Cancer Drugs Market Today?

Major companies operating in the gastric cancer drugs market include F. Hoffmann-La Roche, Eli Lilly and Company, Otsuka Pharmaceutical, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Roche India, Novartis Oncology, Arlak Biotech (India), Healthkind labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz biotech., CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene(China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc (Japan), Daiichi Pharmaceutical and Sankyo (Japan), AQVIDA GmbH, AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Imugene Limited, Merck & Co. Inc., Pfizer Inc., Sandoz AG (A Novartis Division), Eurofarma Laboratórios S.A., TUTEUR ArgentinaPierre Fabre Group, Celnova Pharma, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO), Gulf Pharmaceutical Industries (Julphar), Abbott Laboratories, Mylan Laboratories, Gilead Sciences, BMS, Ascedis Health

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Which Region Is At The Forefront Of Innovation In The Gastric Cancer Drugs Market?

North America was the largest region in the gastric cancer drugs market in 2024. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=2603&type=smp

Browse Through More Reports Similar to the Global Gastric Cancer Drugs Market 2025, By The Business Research Company

Diuretics Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/diuretics-drugs-global-market-report

Genito Urinary Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genito-urinary-drugs-global-market-report

Dermatology Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795